Expression and clinical significance of carcinoembryonic antigen-related cell adhesion molecule 6 in breast cancers

Breast Cancer Research and Treatment

Volumn 142, Issue 2, 2013, Pages 311-322

  Tsang, Julia Y S ^a   Kwok, Ying Kin ^a   Chan, Kit Wing ^a   Ni, Yun Bi ^a   Chow, Wan Ning Vanessa ^b   Lau, Kwok Fai ^b   Shao, Mu Min ^c   Chan, Siu Ki ^d   Tan, Puay Hoon ^e   Tse, Gary M ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^c GUANGZHOU UNIVERSITY OF CHINESE MEDICINE   (China)

^d KWONG WAH HOSPITAL   (Hong Kong)

^e SINGAPORE GENERAL HOSPITAL   (Singapore)

Author keywords

Breast cancer; CEACAM6; HER2; Immunohistochemistry; Nodal stages

Indexed keywords

CARCINOEMBRYONIC ANTIGEN RELATED CELL ADHESION MOLECULE 6; EPIDERMAL GROWTH FACTOR RECEPTOR 2; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER MORTALITY; CANCER PROGNOSIS; CANCER STAGING; DISTANT METASTASIS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRADUCTAL CARCINOMA; INVASIVE CARCINOMA; LYMPH VESSEL METASTASIS; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD; BREAST NEOPLASMS; CELL ADHESION MOLECULES; COHORT STUDIES; DISEASE-FREE SURVIVAL; FEMALE; GPI-LINKED PROTEINS; HUMANS; MIDDLE AGED; PROGNOSIS; RECEPTOR, ERBB-2; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84890425698     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-013-2756-y     Document Type: Article

References (47)

1. Bordes M, Knobel S, Martin F (1975) Carcinoembryonic antigen (CEA) and related antigens in blood cells and hematopoietic tissues. Eur J Cancer 11(11):783-786
2. Scholzel S, Zimmermann W, Schwarzkopf G, Grunert F, Rogaczewski B, Thompson J (2000) Carcinoembryonic antigen family members CEACAM6 and CEACAM7 are differentially expressed in normal tissues and oppositely deregulated in hyperplastic colorectal polyps and early adenomas. Am J Pathol 156(2):595-605. doi: 10.1016/S0002-9440(10)64764-5
3. Blumenthal RD, Leon E, Hansen HJ, Goldenberg DM (2007) Expression patterns of CEACAM5 and CEACAM6 in primary and metastatic cancers. BMC Cancer 7:2. doi: 10.1186/1471-2407-7-2
4. Ilantzis C, DeMarte L, Screaton RA, Stanners CP (2002) Deregulated expression of the human tumor marker CEA and CEA family member CEACAM6 disrupts tissue architecture and blocks colonocyte differentiation. Neoplasia 4(2):151-163. doi: 10.1038/sj/neo/7900201
5. Jantscheff P, Terracciano L, Lowy A, Glatz-Krieger K, Grunert F, Micheel B, Brummer J, Laffer U, Metzger U, Herrmann R, Rochlitz C (2003) Expression of CEACAM6 in resectable colorectal cancer: a factor of independent prognostic significance. J clin oncol 21(19):3638-3646. doi: 10.1200/JCO.2003.55.135
6. Kim KS, Kim JT, Lee SJ, Kang MA, Choe IS, Kang YH, Kim SY, Yeom YI, Lee YH, Kim JH, Kim KH, Kim CN, Kim JW, Nam MS, Lee HG (2012) Overexpression and clinical significance of carcinoembryonic antigen-related cell adhesion molecule 6 in colorectal cancer. Clin Chim Acta 415C:12-19. doi: 10.1016/j.cca.2012.09. 003
7. Duxbury MS, Ito H, Benoit E, Ashley SW, Whang EE (2004) CEACAM6 is a determinant of pancreatic adenocarcinoma cellular invasiveness. Br J Cancer 91(7):1384-1390. doi: 10.1038/sj.bjc.6602113
8. Duxbury MS, Ito H, Benoit E, Waseem T, Ashley SW, Whang EE (2004) A novel role for carcinoembryonic antigen-related cell adhesion molecule 6 as a determinant of gemcitabine chemoresistance in pancreatic adenocarcinoma cells. Cancer Res 64(11):3987-3993. doi: 10.1158/0008-5472.CAN-04-0424
9. Duxbury MS, Ito H, Benoit E, Zinner MJ, Ashley SW, Whang EE (2004) Overexpression of CEACAM6 promotes insulin-like growth factor I-induced pancreatic adenocarcinoma cellular invasiveness. Oncogene 23(34):5834-5842. doi: 10.1038/sj.onc.1207775
10. Duxbury MS, Ito H, Zinner MJ, Ashley SW, Whang EE (2004) CEACAM6 gene silencing impairs anoikis resistance and in vivo metastatic ability of pancreatic adenocarcinoma cells. Oncogene 23(2):465-473. doi: 10.1038/sj.onc.1207036
11. Duxbury MS, Matros E, Clancy T, Bailey G, Doff M, Zinner MJ, Ashley SW, Maitra A, Redston M, Whang EE (2005) CEACAM6 is a novel biomarker in pancreatic adenocarcinoma and PanIN lesions. Ann Surg 241(3):491-496
12. Ieta K, Tanaka F, Utsunomiya T, Kuwano H, Mori M (2006) CEACAM6 gene expression in intrahepatic cholangiocarcinoma. Br J Cancer 95(4):532-540. doi: 10.1038/sj.bjc.6603276
13. Litkouhi B, Fleming E, Welch WR, Berkowitz RS, Birrer MJ, Mok SC (2008) Overexpression of CEACAM6 in borderline and invasive mucinous ovarian neoplasms. Gynecol Oncol 109(2):234-239. doi: 10.1016/j.ygyno.2008.01.031
14. Oue N, Hamai Y, Mitani Y, Matsumura S, Oshimo Y, Aung PP, Kuraoka K, Nakayama H, Yasui W (2004) Gene expression profile of gastric carcinoma: identification of genes and tags potentially involved in invasion, metastasis, and carcinogenesis by serial analysis of gene expression. Cancer Res 64(7):2397-2405
15. Cameron S, Merida de Long L, Hazar-Rethinam M, Topkas E, Endo-Munoz L, Cumming A, Gannon O, Guminski A, Saunders N (2012) Focal overexpression of CEACAM6 contributes to enhanced tumourigenesis in head and neck cancer via suppression of apoptosis. Mol Cancer 11(1):74. doi: 10.1186/1476-4598-11-74
16. Obrink B (1997) CEA adhesion molecules: multifunctional proteins with signal-regulatory properties. Curr Opin Cell Biol 9(5):616-626
17. Ordonez C, Zhai AB, Camacho-Leal P, Demarte L, Fan MM, Stanners CP (2007) GPI-anchored CEA family glycoproteins CEA and CEACAM6 mediate their biological effects through enhanced integrin alpha5beta1-fibronectin interaction. J Cell Physiol 210(3):757-765. doi: 10.1002/jcp.20887
18. Camacho-Leal P, Stanners CP (2008) The human carcinoembryonic antigen (CEA) GPI anchor mediates anoikis inhibition by inactivation of the intrinsic death pathway. Oncogene 27(11):1545-1553. doi: 10.1038/sj.onc.1210789
19. Singer BB, Scheffrahn I, Kammerer R, Suttorp N, Ergun S, Slevogt H (2010) Deregulation of the CEACAM expression pattern causes undifferentiated cell growth in human lung adenocarcinoma cells. PLoS One 5(1):e8747. doi: 10.1371/journal.pone.0008747
20. Blumenthal RD, Hansen HJ, Goldenberg DM (2005) Inhibition of adhesion, invasion, and metastasis by antibodies targeting CEACAM6 (NCA-90) and CEACAM5 (Carcinoembryonic Antigen). Cancer Res 65(19):8809-8817. doi: 10.1158/0008-5472.CAN-05-0420
21. Ihnen M, Kilic E, Kohler N, Loning T, Witzel I, Hagel C, Holler S, Kersten JF, Muller V, Janicke F, Milde-Langosch K (2011) Protein expression analysis of ALCAM and CEACAM6 in breast cancer metastases reveals significantly increased ALCAM expression in metastases of the skin. J Clin Pathol 64(2):146-152. doi: 10.1136/jcp.2010.082602
22. Poola I, Shokrani B, Bhatnagar R, DeWitty RL, Yue Q, Bonney G (2006) Expression of carcinoembryonic antigen cell adhesion molecule 6 oncoprotein in atypical ductal hyperplastic tissues is associated with the development of invasive breast cancer. Clin Cancer Res 12(15):4773-4783. doi: 10.1158/1078-0432.CCR-05-2286
23. Maraqa L, Cummings M, Peter MB, Shaaban AM, Horgan K, Hanby AM, Speirs V (2008) Carcinoembryonic antigen cell adhesion molecule 6 predicts breast cancer recurrence following adjuvant tamoxifen. Clin Cancer Res 14(2):405-411. doi: 10.1158/1078-0432.CCR-07-1363
24. Scott DJ, Parkes AT, Ponchel F, Cummings M, Poola I, Speirs V (2007) Changes in expression of steroid receptors, their downstream target genes and their associated co-regulators during the sequential acquisition of tamoxifen resistance in vitro. Int J Oncol 31(3):557-565
25. Lewis-Wambi JS, Cunliffe HE, Kim HR, Willis AL, Jordan VC (2008) Overexpression of CEACAM6 promotes migration and invasion of oestrogen-deprived breast cancer cells. Eur J Cancer 44(12):1770-1779. doi: 10.1016/j.ejca.2008.05. 016
26. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Eystein Lonning P, Borresen-Dale AL (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98(19):10869-10874. doi: 10.1073/pnas.19136709898/19/ 10869
27. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM (2006) REporting recommendations for tumor MARKer prognostic studies (REMARK). Breast Cancer Res Treat 100(2):229-235. doi: 10.1007/s10549-006-9242-8
28. Elston CW, Ellis IO (1991) Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19(5):403-410
29. Lakhani SR, Ellis IO, Schnitee SJ, Tan PH, van de Vijver MJ (eds) (2012) World Health Organisation classification of tumors of the Breast, 4th edn. IARC Press, Lyon
30. Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M, Hicks DG, Lester S, Love R, Mangu PB, McShane L, Miller K, Osborne CK, Paik S, Perlmutter J, Rhodes A, Sasano H, Schwartz JN, Sweep FC, Taube S, Torlakovic EE, Valenstein P, Viale G, Visscher D, Wheeler T, Williams RB, Wittliff JL, Wolff AC (2010) American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 28(16):2784-2795. doi: 10.1200/JCO.2009.25.6529
31. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, McShane LM, Paik S, Pegram MD, Perez EA, Press MF, Rhodes A, Sturgeon C, Taube SE, Tubbs R, Vance GH, van de Vijver M, Wheeler TM, Hayes DF (2007) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25(1):118-145. doi: 10.1200/JCO.2006.09.2775
32. Cheang MC, Chia SK, Voduc D, Gao D, Leung S, Snider J, Watson M, Davies S, Bernard PS, Parker JS, Perou CM, Ellis MJ, Nielsen TO (2009) Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 101(10):736-750. doi: 10.1093/jnci/djp082
33. Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thurlimann B, Senn HJ (2011) Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St. Gallen international expert consensus on the Primary Therapy of Early Breast Cancer. Ann Oncol 22(8):1736-1747. doi: 10.1093/annonc/mdr304
34. Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, Hernandez-Boussard T, Livasy C, Cowan D, Dressler L, Akslen LA, Ragaz J, Gown AM, Gilks CB, van de Rijn M, Perou CM (2004) Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 10(16):5367-5374. doi: 10.1158/1078-0432.CCR-04-022010/16/5367
35. Han SU, Kwak TH, Her KH, Cho YH, Choi C, Lee HJ, Hong S, Park YS, Kim YS, Kim TA, Kim SJ (2008) CEACAM5 and CEACAM6 are major target genes for Smad3-mediated TGF-beta signaling. Oncogene 27(5):675-683. doi: 10.1038/sj.onc.1210686
36. Wang SE (2011) The functional crosstalk between HER2 tyrosine kinase and TGF-beta signaling in Breast Cancer Malignancy. J Signal Transduct 2011:804236. doi: 10.1155/2011/804236
37. Kim S, Han J, Lee SK, Koo M, Cho DH, Bae SY, Choi MY, Kim JS, Kim JH, Choe JH, Yang JH, Nam SJ, Lee JE (2012) Smad7 acts as a negative regulator of the epidermal growth factor (EGF) signaling pathway in breast cancer cells. Cancer Lett 314(2):147-154. doi: 10.1016/j.canlet.2011.09.024
38. Walters S, Maringe C, Butler J, Rachet B, Barrett-Lee P, Bergh J, Boyages J, Christiansen P, Lee M, Warnberg F, Allemani C, Engholm G, Fornander T, Gjerstorff ML, Johannesen TB, Lawrence G, McGahan CE, Middleton R, Steward J, Tracey E, Turner D, Richards MA, Coleman MP (2013) Breast cancer survival and stage at diagnosis in Australia, Canada, Denmark, Norway, Sweden and the UK, 2000-2007: a population-based study. Br J Cancer 108(5):1195-1208. doi: 10.1038/bjc.2013.6
39. Carter CL, Allen C, Henson DE (1989) Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer 63(1):181-187
40. Fisher ER, Anderson S, Redmond C, Fisher B (1993) Pathologic findings from the national surgical adjuvant breast project protocol B-06. 10-year pathologic and clinical prognostic discriminants. Cancer 71(8):2507-2514
41. Heimann R, Hellman S (2000) Clinical progression of breast cancer malignant behavior: what to expect and when to expect it. J clin oncol 18(3):591-599
42. Khoury T, Kanehira K, Wang D, Ademuyiwa F, Mojica W, Cheney R, Morrison C, Conroy J, Nowak N, Liu S (2010) Breast carcinoma with amplified HER2: a gene expression signature specific for trastuzumab resistance and poor prognosis. Mod Pathol 23(10):1364-1378. doi: 10.1038/modpathol.2010.125
43. Niu G, Murad YM, Gao H, Hu S, Guo N, Jacobson O, Nguyen TD, Zhang J, Chen X (2012) Molecular targeting of CEACAM6 using antibody probes of different sizes. J Control Release 161(1):18-24. doi: 10.1016/j.jconrel.2012.04.043
44. Riley CJ, Engelhardt KP, Saldanha JW, Qi W, Cooke LS, Zhu Y, Narayan ST, Shakalya K, Croce KD, Georgiev IG, Nagle RB, Garewal H, Von Hoff DD, Mahadevan D (2009) Design and activity of a murine and humanized anti-CEACAM6 single-chain variable fragment in the treatment of pancreatic cancer. Cancer Res 69(5):1933-1940. doi: 10.1158/0008-5472.CAN-08-2707
45. Strickland LA, Ross J, Williams S, Ross S, Romero M, Spencer S, Erickson R, Sutcliffe J, Verbeke C, Polakis P, van Bruggen N, Koeppen H (2009) Preclinical evaluation of carcinoembryonic cell adhesion molecule (CEACAM) 6 as potential therapy target for pancreatic adenocarcinoma. J Pathol 218(3):380-390. doi: 10.1002/path.2545
46. Kono K, Sato E, Naganuma H, Takahashi A, Mimura K, Nukui H, Fujii H (2004) Trastuzumab (Herceptin) enhances class I-restricted antigen presentation recognized by HER-2/neu-specific T cytotoxic lymphocytes. Clin Cancer Res 10(7):2538-2544
47. Gelmon K, Dent R, Mackey JR, Laing K, McLeod D, Verma S (2012) Targeting triple-negative breast cancer: optimising therapeutic outcomes. Ann oncol 23(9):2223-2234. doi: 10.1093/annonc/mds067